MANGOCEUTICALS, INC. Enters Material Definitive Agreement
Ticker: MGRX · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $150,000, $50,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Mangoceuticals just signed a big deal with a new financial obligation. Keep an eye on this.
AI Summary
On October 18, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Texas with its principal executive offices in Dallas, filed this 8-K report on October 22, 2024.
Why It Matters
This filing indicates MANGOCEUTICALS, INC. has entered into a significant agreement that creates a financial obligation, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce financial risks and uncertainties for a company.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- October 18, 2024 (date) — Date of Earliest Event Reported
- Texas (jurisdiction) — State of Incorporation
- Dallas (location) — Principal Executive Offices
- October 22, 2024 (date) — Filing Date
FAQ
What type of material definitive agreement did MANGOCEUTICALS, INC. enter into?
The filing states that MANGOCEUTICALS, INC. entered into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What is the nature of the direct financial obligation created by this agreement?
The filing indicates the creation of a direct financial obligation, but the specific terms and amount of this obligation are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 18, 2024.
Where are MANGOCEUTICALS, INC.'s principal executive offices located?
MANGOCEUTICALS, INC.'s principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the filing date of this 8-K report?
This 8-K report was filed on October 22, 2024.
Filing Stats: 1,139 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2024-10-22 08:00:11
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $150,000 — y ", " we " and " us "), entered into a $150,000 promissory note (the " Cohen Note ") wi
- $50,000 — evidence, document and memorialize (a) $50,000 loaned to the Company from Cohen Enterp
- $100,000 — Enterprises on March 18, 2024, and (b) $100,000 loaned to the Company from Cohen Enterp
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 72KB
- ex99-1.htm (EX-99.1) — 20KB
- 0001493152-24-041885.txt ( ) — 336KB
- mgrx-20241018.xsd (EX-101.SCH) — 3KB
- mgrx-20241018_lab.xml (EX-101.LAB) — 33KB
- mgrx-20241018_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 22, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer